Immune profiling in diffuse large B-cell lymphoma and mantle cell lymphoma patients treated with autologous hematopoietic cell transplant

• Published in: Bone marrow transplantation (Basingstoke) Vol. 55; no. 1; pp. 77 - 85
• Main Authors: Herr, Megan M., Torka, Pallawi, Zhang, Yali, Wallace, Paul K., Tario, Joseph D., Repasky, Elizabeth A., Chen, George L., Ho, Christine M., Balderman, Sophia R., Ross, Maureen, Paiva, Bruno, Hernandez-Ilizaliturri, Francisco J., McCarthy, Philip L., Hahn, Theresa
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.01.2020; Nature Publishing Group
• Subjects: 13/31; 631/250/1904; 631/67/1990/291/1621/1915; Autografts; B cells; B-cell lymphoma; Biomarkers; Care and treatment; CD4 antigen; CD8 antigen; Cell Biology; Cell survival; Correlation analysis; Effector cells; Ethylenediaminetetraacetic acid; Granulocyte colony-stimulating factor; Hematology; Hematopoietic stem cells; Immune reconstitution; Immunological memory; Internal Medicine; Lymphocytes B; Lymphocytes T; Lymphoma; Mantle; Mantle cell lymphoma; Medicine; Medicine & Public Health; Memory cells; Non-Hodgkin's lymphoma; Non-Hodgkin's lymphomas; Patients; Prognosis; Public Health; Remission; Stem cell transplantation; Stem Cells; Survival; T cells; Transplantation
• ISSN: 0268-3369; 1476-5365
• DOI: 10.1038/s41409-019-0591-4

This is the first longitudinal study of immune profiles and autologous hematopoietic cell transplant (AHCT) survival in B-cell non-Hodgkin lymphoma (B-NHL) patients and the effect of plerixafor mobilization on immune reconstitution in this population. A comprehensive immunophenotyping panel was performed in 104 consecutive adult B-NHL patients (58% diffuse large B cell and 42% mantle cell) who received AHCT (1/2008–11/2014), at a median of 28 days pre-AHCT ( N  = 104) and Day +100 ( N  = 83) post-AHCT. Median follow-up post-AHCT was 61 months (range: 8–120 months). Compared to patients mobilized with filgrastim and plerixafor, patients mobilized with filgrastim alone had a higher proportion of CD4+ naïve ( p  = 0.006) and CD8+ central memory T-cells ( p  = 0.006) pre-AHCT. For patients transplanted in complete remission (CR), a higher proportion of CD8+ effector memory T-cells pre-AHCT was associated with worse progression-free survival (PFS; p  < 0.01) and overall survival (OS; p  < 0.01). A higher ratio of CD8:CD4+ central memory T-cells pre-AHCT was associated with worse PFS ( p  < 0.0001) and OS ( p  = 0.0034). This same ratio measured post-AHCT among patients in CR on Day +100 was associated with worse and OS ( p  = 0.008) but not PFS ( p  = not significant). These immune subsets are complementary biomarkers which identify patients transplanted in CR who have poor survival prognoses and may warrant further clinical interventions.